Zacks: Analysts Anticipate Nabriva Therapeutics PLC – (NASDAQ:NBRV) Will Post Quarterly Sales of $1.07 Million

Brokerages expect that Nabriva Therapeutics PLC – (NASDAQ:NBRV) will report sales of $1.07 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Nabriva Therapeutics’ earnings, with the lowest sales estimate coming in at $680,000.00 and the highest estimate coming in at $1.45 million. Nabriva Therapeutics posted sales of $1.70 million during the same quarter last year, which would indicate a negative year over year growth rate of 37.1%. The company is expected to issue its next quarterly earnings results on Friday, May 8th.

On average, analysts expect that Nabriva Therapeutics will report full-year sales of $12.40 million for the current fiscal year, with estimates ranging from $4.02 million to $25.00 million. For the next year, analysts forecast that the firm will post sales of $35.46 million, with estimates ranging from $10.47 million to $70.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. Nabriva Therapeutics had a negative net margin of 872.95% and a negative return on equity of 179.92%. The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $1.60 million.

Several analysts recently issued reports on the stock. Needham & Company LLC dropped their price objective on shares of Nabriva Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, March 13th. Morgan Stanley lowered shares of Nabriva Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $7.00 to $2.00 in a report on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Nabriva Therapeutics in a report on Friday, March 13th. ValuEngine lowered shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Zacks Investment Research upgraded shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Thursday, March 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $4.59.

Hedge funds have recently modified their holdings of the company. State Street Corp acquired a new position in shares of Nabriva Therapeutics in the 3rd quarter worth approximately $65,000. Banco Bilbao Vizcaya Argentaria S.A. acquired a new position in shares of Nabriva Therapeutics in the 4th quarter worth approximately $198,000. Millennium Management LLC lifted its holdings in shares of Nabriva Therapeutics by 551.1% in the 3rd quarter. Millennium Management LLC now owns 333,364 shares of the biotechnology company’s stock worth $666,000 after acquiring an additional 282,164 shares during the last quarter. Clear Creek Financial Management LLC lifted its holdings in shares of Nabriva Therapeutics by 111.3% in the 4th quarter. Clear Creek Financial Management LLC now owns 112,000 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 59,000 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Nabriva Therapeutics by 23.6% in the 4th quarter. FMR LLC now owns 6,131,900 shares of the biotechnology company’s stock worth $8,094,000 after acquiring an additional 1,172,200 shares during the last quarter. Hedge funds and other institutional investors own 3.25% of the company’s stock.

NASDAQ NBRV traded down $0.08 during trading hours on Monday, hitting $0.53. 2,546,262 shares of the company’s stock traded hands, compared to its average volume of 1,583,823. Nabriva Therapeutics has a 52-week low of $0.50 and a 52-week high of $3.19. The company has a market capitalization of $544.08 million, a PE ratio of -0.47 and a beta of 2.41. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.48 and a quick ratio of 5.44. The firm’s 50-day moving average is $1.12 and its 200-day moving average is $1.59.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Article: Initial Coin Offerings entail a high degree of risk

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.